Acute urticaria associated with omalizumab treatment in patients with childhood asthma. Analysis of a clinical case;Urticaria aguda asociada con el tratamiento con omalizumab en pacientes con asma infantil. Análisis de un caso clínico

Revista Alergia Mexico

Volumn 59, Issue 4, 2012, Pages 209-213

  Velarde Domínguez, Tomas ^a   Martínez Sáenz, Nancy P ^b   Pantoja Alcántar, J Manuel ^c  

^a Unidad de Especialidades Médicas   (Mexico)

^b HOSPITAL REGIONAL LIC ADOLFO LÓPEZ MATEOS   (Mexico)

^c NONE

Author keywords

Acute urticaria; Anti IgE therapy; Asthma; Omalizumab

Indexed keywords

OMALIZUMAB; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; ALLERGIC ASTHMA; ARTICLE; CASE REPORT; CHILD; CONSCIOUSNESS DISORDER; DIZZINESS; DRUG SAFETY; ERYTHEMA; FEMALE; HEADACHE; HUMAN; PALLOR; SCHOOL CHILD; SIDE EFFECT; SWEATING; TREATMENT RESPONSE; URTICARIA; ASTHMA; CHURG STRAUSS SYNDROME; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; CHURG-STRAUSS SYNDROME; HUMANS; OMALIZUMAB; URTICARIA;

EID: 84878499086     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. European Medicines Agency (EMEA). Assessment report for Xolair. EMEA/493707/2009. London: EMEA;2009.
2. US Food and Drug Administration. Early communication about an ongoing safety review of omalizumab (marketed as Xolair)-. Federal Drug Administration advisory for omalizumab.2009. Avaliable at:http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor-PatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm172218.htm?sms-ss= email&at-xt=4d91ffic721cf3461%2C0:[Last accessed: 8 May 2011].
3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Actualization 2010. Available from: http://www.ginasthma.com/ Guidelineitem.asp?l1=2&l2=1&intId=60:[Last accessed: 8 May 2011].
4. NICE technology appraisal guidance 133 2010. Omalizumab for severe persistent allergic asthma. Actualization 2010. Available at: http://www.nice.org.uk/nicemedia/live/11894/38392/38392.pdf:[Last accessed: 8 May 2011].
5. Tan R, Corren J. Safety of omalizumab in asthma; Expert Opin Drug Saf 2011;3:463-71.
6. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, 19;(2):CD003559.
7. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114:265-9 (Pubitemid 39119022)
8. http://www.ema.europa.eu/docs/es-ES/document-li-brary/ EPAR-Product-Information/human/000606/WC500057298.pdf
9. http://www.americaalimentos.com/pdf/aminoacidos/LHisti- dina%20HCL%20AMI0005.pdf
10. Chuan-Long Hsu a, Yu-Yu Shiung b, Bai-Ling Lin c, Hwan-You Chang a, Tse Wen Chang. Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model. Int Immunopharmacol 2010; 10: 533-539
11. Pascal Chanez, Cecile Contin-Bordes, Gilles Garcia, et all. Omalizumab-induced decrease of Fc3RI expression in patients with severe allergic asthma: Respir Med 2010; 104, 1608-1617